Bionano Genomics, Inc. — Director's Dealing 2018

Aug 21, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BioNano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2018-08-21

Reporting Person: Zhou Quan (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Convertible Preferred Stock	$0.00		Common Stock (8545184)		Indirect
Series D Convertible Preferred Stock	$0.00		Common Stock (6443565)		Indirect
Series D-1 Convertible Preferred Stock	$0.00		Common Stock (27305708)		Indirect
Series D Convertible Preferred Stock Warrants (Right to Buy)	$0.41	2026-03-04	Series D Convertible Preferred Stock (11263624)		Indirect

Footnotes

F1: The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock.

F2: The shares are held as follows: 8,203,376 shares held by LC Fund VI, L.P. ("LC Fund") and 341,808 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.

F3: The shares are held as follows: 6,143,224 shares held by LC Fund and 300,341 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.

F4: The shares are held as follows: 3,924,722 shares held by LC Fund, 241,948 shares held by Parallel Fund and 23,139,038 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.

F5: The warrants are held as follows: warrant to purchase 10,738,615 shares held by LC Fund and warrant to purchase 525,009 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.